To Study the effect of Empagliflozin on the cardiovascular biomarkers in diabetic patients myocardial infarctio

Phase 4

• Conditions: Condition 1: Myocardial Infarction. Condition 2: Type 2 diabetes.; Acute transmural myocardial infarction of unspecified site; Type 2 diabetes mellitus without complications; I21.3; E11.9

• Registration Number: IRCT20230724058910N1
• Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Type 2 diabetic patients (Hb A1C: 6.5-8)
Diabetes treated with oral agents
Typical chest pain during the 12 hours before presentation lasting more than 30 minutes
ST- segment elevation above 0.1 mV in two leads or more in ECG

Exclusion Criteria

Cardiogenic shock
Diabetic ketoacidosis
History of CABG
Type 1 diabetic patients
Severe liver failure
End stages cancer or history of any cancer
History of severe allergy to empagliflozin or its formulation components
Severe renal failure (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis
Hypovolemia
Any inflammatory disease under treatment
Advanced heart failure
Hypoglycemia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Galectin-3 gene expression. Timepoint: Measurement of Galectin-3 gene expression at the beginning of the study (before intervention) and 3 months after starting empagliflozin. Method of measurement: RT-PCR.;SST2 gene expression. Timepoint: Measurement of sST2 gene expression at the beginning of the study (before intervention) and 3 months after starting empagliflozin. Method of measurement: RT-PCR.